SALT LAKE CITY, UT / ACCESSWIRE / December 9, 2015 / An array of small biotech companies are making waves in the industry by presenting new, alternative medicines and therapies that perform better than their predecessors, while often available at a lower cost.

One such company making significant progress in development and distribution in recent weeks is Cannabis Sciences, Inc (OTC: CBIS). Notable for being one of the first-ever publicly-traded cannabinoid companies, Cannabis Science is at the forefront of the creation of medicinal cannabinoid therapies. Legal cannabis-based products jumped 74% in 2014 and is expected to be a $10.2 billion market by 2018. Recently, Cannabis Sciences has ramped up production and distribution of several of these therapies, which offer long-lasting relief and treatment for ailments that are often difficult and expensive to treat, such as cancer, AIDS, arthritis, and others.

CBIS reached a company milestone in California by launching a product line of cannabinoid-formulated capsules to several dispensaries throughout the state, which includes the debut of several new capsules like high potency CBD, Indica, and Sativa at events like Emerald Cup, a cannabis expo in Santa Rosa.

Behind the scenes, the company took a major step in early November with the announcement of a collaborative drug development deal with IGXBio Inc. In addition to working on joint protocols to evaluate current products, the partnership leaves the door open for the creation of brand new drug candidates using the established methods of both companies. The move advances the clinical reputation of Cannabis Sciences thanks to IGXBio's recent approval in human trials for one of its experimental medications, GenePro.

CBIS President and CEO acknowledged the company's willingness to accelerate its collaborative drug development program, and these moves represent major strides for a company whose drug candidates were in an early, fledgling status as recently as last year. Cannabis Sciences even stands on the verge of widely expanding its animal health-care product line through its wholly-owned subsidiary, Equi-Farm. In fact, an e-commerce website featuring seven of the new cannabinoid-based therapies for various animals is set to be launched this month.

Also on the horizon in alternative biotech therapies are two new technologies from companies attempting to streamline the process of diagnosis for major diseases. Spectrascience Inc. (SCIE), a microcap stock which is a company developing a potentially groundbreaking light technology to determine whether human tissue is cancerous or pre-cancerous, without requiring the removal of tissue through a medical procedure. Such a procedure could revolutionize the process of cancer diagnosis. Similarly, Guided Therapeutics, Inc. (OTC: GTHP), just shipped its first order of LuViva cervical scan disposables, a technology that also uses light as a painless, efficient test for early detection of the beginning cellular stages of cervical cancer. The flagship products of these companies exemplify a new wave of diagnostic medicine on par with Cannabis Bioscience's new wave of therapeutic medicine.

Investors may also want to take a look at some recently surging stock, including Anavex Life Sciences Corp. (NASDAQ: AVXL) currently trading at 6.73 per share. The company's stock price has jumped in recent weeks thanks to some promising data trickling in for ANAVEX 3-71. Research has shown that the drug may be effective for reducing synaptic loss in Alzheimer's patients, meaning an increase in cognition for patients suffering from a disease with few other alternative medicines.

Another surging stock on the horizon is CD International Enterprises (OTC: CDII), an industrial commodities and corporate consulting company based in China and the Americas whose price soared over 4,000 percent at the height of trading last week, based on the news that the company received a purchase order of 240K tons of copper concentrate, valued at $350M.

Given recent fluctuations in global markets, the time may be right for investors to take a flier on smaller stocks with big aspirations and even bigger innovations. Given its recent progress, Cannabis Biosciences (CBIS) can be viewed as a spearheading force in a small group of companies that may currently developing the future of biotech treatments and diagnostic therapies.

Seraphim Strategies is a third party publisher. Not a registered broker/dealer/analyst/adviser, holds no investment licenses and may not sell, offer to sell or offer to buy any security. Market updates, news alerts and corporate profiles are not a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is not to be interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. For full disclaimer please read http://tomorrowsbluechips.com/disclaimer/ This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

"Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually," or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.

SOURCE: Seraphim Strategies LLC